Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma

To the Editor: Multiple myeloma (MM) is currently considered to be an incurable neoplasm and a systemic disease, and the first line of treatment plays a crucial role in MM patients, since the majority of patients do not survive beyond the first-line treatment.[1] Lenalidomide, a first-line drug in the treatment of MM, is sold as a capsule under the trade name Revlimid®, which is in great demand for an increasing incidence of MM. Additionally,...